This study was performed to measure the possible persistence of formaldehyde, the active substance of formalin solution, in seawater and edible gilthead seabream (Sparus aurata) tissues after a formalin bath. The trial was carried out during the summer period as parasitic infestations are of a high frequency. Water samples were taken within or at a short distance from the treatment cages, during and following formalin immersion. Fish fillets were also sampled at the same sampling points. Chromatographic analysis of water and tissue samples was performed with a photodiode array detector (HPLC-PDA). Measured formaldehyde concentrations in gilthead seabream fillets clearly showed no increase due to the immersion or advent of time. Formaldehyde measurements in seawater revealed that after formalin treatments negligible amounts of the substance remain in the aquatic environment and these values seem to be relatively unaffected by depth in the vicinity of the fish cages. Further research is required to investigate the formalin degradation cycle under Mediterranean seawater conditions, including more farm sites and temperature ranges.
The tandem Tudor domain (TTD) of UHRF1 is a compelling epigenetic target for novel cancer therapeutics. Here, we integrate theoretical simulations, sophisticated biophysical evaluations and cellular assays to characterize potent TTD binders. Screening of small drug‐ and fragment‐like collections identifies several TTD ligands, with the most promising hit being the local anesthetic hydroxyprocaine. The ligand is characterized in terms of its binding requisites by calorimetry, affording a Kd of 1.46 μM and a well‐balanced thermodynamic profile. Molecular dynamics simulations combined with heat capacity measurements and osmotic stress titrations confirm that hydroxyprocaine binds stably to the TTD by displacing approximately 26 interfacial water molecules upon complexation. A targeted follow‐up screen focusing on sodium channel blockers yields two additional, although less promising hits, mexiletine and triamterene. In the DU145 prostate cancer cell line, hydroxyprocaine treatment significantly up‐regulates key downstream targets including the tumor‐suppressor p53 and, to a lesser degree, the stress and inflammation regulators p38 and p65, respectively, while exhibiting very low cytotoxicity. Finally, a previously undocumented interdomain interaction between TTD and its N‐terminal adjacent Ubiquitin‐like domain is reported, introducing a novel, potentially druggable UHRF1 regulatory feature. Together, these findings establish hydroxyprocaine as a highly viable chemical scaffold for TTD‐targeted drug development.